CytoDyn CEO says FDA has offered 'a good path forward' for its HIV drug
CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassen tells Proactive Investors the biotech held a productive phone conversation with the FDA in which it won key concessions for its flagship HIV drug leronlimab.
Pourhassen says regulators offered 'a good path forward' for leronlimab, as they recognized the higher dosage of 700mg in a monotherapy trial for leronlimab, an injectable antibody that takes aim at HIV, had a much higher response rate than the 350mg dose used in a combination therapy trial. Pourhassen says the company will now submit a Biologics License Application (BLA) to move the drug forward.
Quick facts: CytoDyn